ArticleHealthcare (Basel, Switzerland)2025
Cost-Effectiveness Analysis of Recombinant Tumor Necrosis Factor Receptor: Fc Fusion Protein as First-Line Treatment for Active Rheumatoid Arthritis in China.
Rui Zhang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.